Your browser doesn't support javascript.
loading
Description of a pharmacist-driven safety algorithm in Staphylococcus aureus bacteremia: Compliance, interventions, and good saves.
Lines, Tara H; Nesbitt, Whitney J; Greene, Matthew H; Nelson, George E.
Afiliación
  • Lines TH; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Nesbitt WJ; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Greene MH; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Nelson GE; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Infect Control Hosp Epidemiol ; 41(8): 921-925, 2020 08.
Article en En | MEDLINE | ID: mdl-32539873
ABSTRACT

OBJECTIVE:

To evaluate the impact of a pharmacist-driven Staphylococcus aureus bacteremia (SAB) safety bundle supported by leadership and to compare compliance before and after implementation.

DESIGN:

Retrospective cohort study with descriptive and before-and-after analyses.

SETTING:

Tertiary-care academic medical center. PATIENTS All patients with documented SAB, regardless of the source of infection, were included. Patients transitioned to palliative care were excluded from before-and-after analysis.

METHODS:

A pharmacist-driven safety bundle including documented clearance of bacteremia, echocardiography, removal of central venous catheters, and targeted intravenous therapy of at least 2 weeks duration was implemented in November 2015 and was supported by leadership with stepwise escalation for nonresponse. A descriptive analysis of all patients with SAB during the study period included pharmacy interventions, acceptance rates, and escalation rates. A pre-post implementation analysis of 100 sequential patients compared bundle compliance and descriptive parameters.

RESULTS:

Overall, 391 interventions were made in the 20-month period following implementation, including 20 "good saves" avoiding potentially major adverse events. No statistically significant differences in complete bundle compliance were detected between the periods (74% vs 84%; P = .08). However, we detected a significant increase in echocardiography after the bundle was implemented (83% vs 94%; P = .02) and fewer patients received suboptimal definitive therapy after the bundle was implemented (10% vs 3%; P = .045).

CONCLUSIONS:

This pharmacist-driven SAB safety bundle with leadership support showed improvement in process measures, which may have prevented major adverse events, even with available infectious diseases (ID) consultation. It provides a critical safety net for institutions without mandatory ID consultation or with limited antimicrobial stewardship resources.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Staphylococcus aureus / Bacteriemia Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Infect Control Hosp Epidemiol Asunto de la revista: DOENCAS TRANSMISSIVEIS / ENFERMAGEM / EPIDEMIOLOGIA / HOSPITAIS Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Staphylococcus aureus / Bacteriemia Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Infect Control Hosp Epidemiol Asunto de la revista: DOENCAS TRANSMISSIVEIS / ENFERMAGEM / EPIDEMIOLOGIA / HOSPITAIS Año: 2020 Tipo del documento: Article